A man with type 1 diabetes has become the first patient to produce his insulin after receiving genetically engineered cell transplants, without the need for drugs to prevent rejection. The case, published this month in the New England Journal of Medicine, is being hailed as a potential breakthrough in treating a disease that affects about 9.5 million people worldwide.
Type 1 diabetes damages insulin-producing cells
Type 1 diabetes occurs when the immune system destroys islet cells in the pancreas. These specialized cells produce insulin, the hormone that regulates blood sugar. The condition can be managed with regular injections of synthetic insulin, but there is currently no cure.
Traditional transplants face immune rejection
One approach to restoring insulin production is through islet cell transplants. However, the immune system often identifies transplanted cells as foreign and attacks them, destroying the new tissue. To prevent this, patients must take lifelong immunosuppressive drugs, which increase the risk of serious infections.
CRISPR technology used to modify donor cells
Researchers in Sweden and the United States sought to bypass this problem by utilizing CRISPR gene-editing technology to modify donor islet cells from a human pancreas. The edits were designed to make the cells invisible to the recipient’s immune system. This marks the first time such a method has been tested in a human patient.
Today's big biotech win is that we might be on the verge of a cure for type-1 diabetes🧵
Twelve diabetics were injected with stem cell-derived pancreatic islets.
They started producing insulin again.
One year in, 10/12 participants no longer needed to inject insulin. pic.twitter.com/wFDtAsqJiY
— Crémieux (@cremieuxrecueil) June 21, 2025
Twelve weeks after receiving the modified cells, the man continues to produce insulin without signs of immune rejection.
Three edits reduce immune detection
In their report, the authors noted that, although the study is in its early stages, the results suggest genetic engineering could be a promising strategy for preventing rejection of transplanted cells or organs.
To achieve this effect, researchers made three changes to the donated cells’ genetic code. Two edits reduced the levels of surface proteins that signal to white blood cells whether a cell is foreign or not. The third boosted production of CD47, a protein that acts as a “don’t attack” signal to other immune cells.
Modified cells survive and function in the patient
The modified cells were injected into the patient’s forearm. They survived without being targeted by the immune system and produced insulin as normal.
Because the patient received only a small dose of the edited cells, he still requires daily insulin therapy. However, the procedure demonstrated that the technique can be performed safely.
Next steps in research
The research team plans follow-up studies to determine whether the cells can survive and function long term. If they do, the approach could significantly ease disease treatment and may one day lead to a cure. Further trials will also be necessary to determine if the treatment works for other patients.
See all the latest news from Greece and the world at Greekreporter.com. Contact our newsroom to report an update or send your story, photos and videos. Follow GR on Google News and subscribe here to our daily email!


